Humanized or chimeric CD3 antibodies
US11613575B2 · kind B2 · utility
3Cited by
6References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 19, 2019 |
| Grant date | Mar 28, 2023 |
| Priority date | — |
| Expiry date | Jun 7, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.